REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT ...

The Cigna Group (CI) Q1 2025 Earnings Call May 02, 2025 08:30 AM ET Company Participants Ralph Giacobbe - Senior VP - IRDavid Cordani - Chairman & Chief Executive OfficerBrian Evanko - President & COOAnn Dennison - EVP & CFOLisa Gill - Managing DirectorA.J. Rice - Managing DirectorCharles Rhyee - Managing DirectorAndrew Mok - DirectorJoshua Raskin - Partner - Managed Care & Providers Conference Call Participants Justin Lake - Analyst - Healthcare ServicesAnn Hynes - Senior Healthcare Services Equity Analyst ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USDup by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of 2024 acquisition of US biosimilar Cimerli® (ranibizumab) and 2024 divestment of China businessten largest-selling medicines grew by combined 4% and represented 33% of net sales Europe net sales grew by 7%[1]. International declined by 2%[1] and increased by 2 ...

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to develop and manufacture biosimilar, with Sandoz to register and commercialize after expiry of relevant patents across global marketsCombination therapy of ipilimumab and nivolumab used in 95% of eligible patients[2]; ipilimumab highly complementary to proposed Sandoz nivolumab biosimilarPotential to address con ...

报告行业投资评级 - 行业观点为“与大市一致” [7] 报告的核心观点 - 对美国药品市场进行全面分析，涵盖总处方量同比增长、关键产品销售情况、生物类似药采用情况等多方面内容 [1][2] 各部分总结 市场整体情况 - 截至4月11日当周，美国药品市场总处方量同比增长2.7%，前一周为3.5%，过去12周均为2.7% [1][2] - 扩展单位（EUTRx）周同比增长1.4%，低于总处方量同比增长 [2] - 连续周总处方量增长为0.3%，前一周为1.3% [2] 关键产品情况 BMY的Cobenfy - 2024年9月26日获批用于精神分裂症，本周处方量约1660份，上周约1580份 [3] - 要达到2025年市场共识预期，Cobenfy总处方量需达到类似药物上市时的2 - 3倍 [3] VRTX的Journavx - 2025年1月30日获批用于急性疼痛，本周处方量约2950份，上周约2650份 [4] - 预计平均处方量为35 - 37片，患者主要获得14天或更长时间的处方 [4] 生物类似药情况 - 列出多种生物类似药的美国批准/上市时间线，如Amgen的Wezlana于2025年1月17日上市 [48] - 分析部分生物类似药的市场份额，如Avastin、Actemra、Herceptin等 [50][54][57] 各治疗领域情况 心血管领域 - 抗凝血剂中，Eliquis、Xarelto等药物的处方量同比有不同变化 [90][92] - 降脂药物中，AMGN的Repatha处方量同比增长36%，Sanofi的Praluent同比下降9% [100] 糖尿病领域 - DPP - 4、SGLT - 2和GLP - 1类药物的处方量份额各有不同，GLP - 1类药物占比61% [111][113] - 部分药物如Januvia Franchise、Onglyza Franchise等的处方量同比有下降趋势 [120] 免疫学领域 - 列出多种自身免疫药物的作用机制和批准适应症 [169] - 分析IL - 17、IL - 23和JAK抑制剂等药物的处方量市场份额和同比增长情况 [182][185] 传染病领域 - HCV药物中，Mavyret处方量市场份额为62%，Epclusa为34% [241] - HIV整合酶抑制剂中，Biktarvy处方量市场份额为60% [243]

Kamada Ltd. (NASDAQ:KMDA) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ET Company Participants Brian Ritchie – LifeSci Advisors Amir London – Chief Executive Officer Chaime Orlev – Chief Financial Officer Conference Call Participants Annabel Samimy – Stifel Anthony Petrone – Mizuho Group James Sidoti – Sidoti & Co. Operator Greetings, and welcome to the Kamada Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. A brief question-and-a ...

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President and Chief Commercial Officer, Specialty Jason Daly - Chief Legal Officer Conference Call Participants Chris Schott - J.P. Morgan David Amsellem ...

Amneal Pharmaceuticals (AMRX) Q4 2024 Earnings Call February 28, 2025 08:30 AM ET Company Participants Anthony DiMeo - Senior Director of Investor RelationsChirag Patel - Co-Founder, Co-CEO, President & DirectorChintu Patel - Co-Founder, Co-CEO & DirectorTasos Konidaris - Executive Vice President, Chief Financial OfficerChris Schott - Managing DirectorJoe Renda - Senior VP & Chief Commercial Officer of SpecialtyLes Sulewski - VP - Biotech Equity ResearchJason Daly - Senior VP, Chief Legal Officer & Corporat ...